tiprankstipranks
Advertisement
Advertisement

CH:GILD Stock Latest News

Gilead: Durable HIV Franchise and Emerging Oncology Pipeline Support Buy Rating and Upside to $162 Target
RatingsGilead: Durable HIV Franchise and Emerging Oncology Pipeline Support Buy Rating and Upside to $162 Target
30m ago
GILD
Gilead announces investment in lenacapavir by PEPFAR, The Global Fund
PremiumThe Fly
Gilead announces investment in lenacapavir by PEPFAR, The Global Fund
20h ago
GILD
Gilead put volume heavy and directionally bearish
PremiumThe Fly
Gilead put volume heavy and directionally bearish
2d ago
GILD
Gilead price target raised to $165 from $156 at Citi
PremiumThe Fly
Gilead price target raised to $165 from $156 at Citi
2d ago
GILD
Gilead price target raised to $175 from $171 at Morgan Stanley
PremiumThe Fly
Gilead price target raised to $175 from $171 at Morgan Stanley
5d ago
GILD
MacroGenics upgraded to Buy at B. Riley after deal for Tubulus
PremiumThe FlyMacroGenics upgraded to Buy at B. Riley after deal for Tubulus
5d ago
GILD
MGNX
Tempus AI announce strategic collaboration with Gilead
Premium
The Fly
Tempus AI announce strategic collaboration with Gilead
6d ago
TEM
GILD
Kymera Therapeutics announces Gilead option exercise to license KT-200
Premium
The Fly
Kymera Therapeutics announces Gilead option exercise to license KT-200
6d ago
GILD
KYMR
Gilead price target raised to $155 from $152 at Truist
PremiumThe Fly
Gilead price target raised to $155 from $152 at Truist
7d ago
GILD
Gilead price target raised to $155 from $152 at Truist
PremiumThe Fly
Gilead price target raised to $155 from $152 at Truist
7d ago
GILD
Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
PremiumRatings
Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
7d ago
GILD
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
PremiumRatings
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
7d ago
GILD
Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
PremiumRatingsGilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
7d ago
GILD
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
Premium
The Fly
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
8d ago
GILD
IMNM
Leerink sees Gilead’s $5B Tubulis buy as ‘more than an oncology bolt-on’
Premium
The Fly
Leerink sees Gilead’s $5B Tubulis buy as ‘more than an oncology bolt-on’
8d ago
GILD
Gilead price target raised to $123 from $118 at RBC Capital
PremiumThe Fly
Gilead price target raised to $123 from $118 at RBC Capital
8d ago
GILD
Gilead to acquire Tubulis for $3.15B upfront, up to $1.85B in milestone payments
PremiumThe Fly
Gilead to acquire Tubulis for $3.15B upfront, up to $1.85B in milestone payments
8d ago
GILD
Compugen initiated with a Buy at Lake Street
PremiumThe Fly
Compugen initiated with a Buy at Lake Street
8d ago
AZN
MRK
Assembly Biosciences price target raised to $43 from $39 at Guggenheim
PremiumThe Fly
Assembly Biosciences price target raised to $43 from $39 at Guggenheim
9d ago
ASMB
GILD
Gilead extends tender offer to acquire Arcellx
PremiumThe FlyGilead extends tender offer to acquire Arcellx
14d ago
ACLX
GILD
Galapagos, Gilead enter pact to collaborate on T cell engager therapies
Premium
The Fly
Galapagos, Gilead enter pact to collaborate on T cell engager therapies
15d ago
GILD
GLPG
Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig
Premium
The Fly
Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig
22d ago
CGEM
GILD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >